Evidence map›Paper›PMID 41204877›Full record

ArticleHuman brain mapping2025

Brain Connectivity Gradients Alterations in Discordant Cerebrospinal Fluid Profile for Alzheimer's Disease Biomarkers.

Lorenzo Pini, Chiara Tuzzato, Alessandra Griffa, Lorenza Brusini, Federica Cruciani, Gilles Allali, Maurizio Corbetta, Gloria Menegaz, Ilaria Boscolo Galazzo, Alzheimer's Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Human brain mapping, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lorenzo PiniDepartment of Neuroscience, University of Padova, Padua, Italy.ORCID 0000-0002-9305-3376
Chiara TuzzatoVeneto Institute of Molecular Medicine (VIMM), Padua, Italy.
Alessandra GriffaLeenaards Memory Center, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-1923-1653
Lorenza BrusiniDepartment of Engineering for Innovation Medicine, University of Verona, Verona, Italy.ORCID 0000-0001-5357-5180
Federica CrucianiDepartment of Engineering for Innovation Medicine, University of Verona, Verona, Italy.ORCID 0000-0001-7258-1463
Gilles AllaliLeenaards Memory Center, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-4455-6719
Maurizio CorbettaDepartment of Neuroscience, University of Padova, Padua, Italy.ORCID 0000-0001-8295-3304
Gloria MenegazDepartment of Engineering for Innovation Medicine, University of Verona, Verona, Italy.ORCID 0000-0002-6889-3461
Ilaria Boscolo GalazzoDepartment of Engineering for Innovation Medicine, University of Verona, Verona, Italy.ORCID 0000-0002-4153-3749
Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
AbbVieAlzheimer's AssociationAlzheimer's Disease Neuroimaging InitiativeAlzheimer's Drug Discovery FoundationAraclon BiotechBioClinica Inc.BiogenBristol-Myers Squibb CompanyCereSpir Inc.CIHRCogstateDOD ADNI W81XWH-12-2-0012Eisai Inc.Elan Pharmaceuticals Inc.Eli Lilly and CompanyEuroImmunF. Hoffmann-La Roche Ltd.Fondazione Cariparo 68076Foundation for the National Institutes of HealthFujirebioGE HealthcareGenentech Inc.HORIZON-ERC-SyG 101071900HORIZON-INFRA-2022 101147319IXICO Ltd.Janssen Alzheimer Immunotherapy Research & Development LLC.Johnson & Johnson Pharmaceutical Research & Development LLC.LumosityLundbeckMerck & Co. Inc.Meso Scale Diagnostics LLC.MIUR D.M. 737/2021MUR PRIN 2022 202292PHR2NEUROCONN RF-2018-1236689NeuroRx ResearchNeurotrack TechnologiesNIA NIH HHS U01 AG024904NIBIB NIH HHSNIH HHS U01 AG024904Northern California Institute for Research and EducationNovartis Pharmaceuticals CorporationPfizer Inc.Piramal ImagingServierSwiss National Science Foundation (SNSF) IZSEZ0_229208Takeda Pharmaceutical CompanyThe Ministero della Salute ItalianoTransition Therapeutics
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a heterogeneous disorder characterized by brain accumulation of amyloid-beta (Aß, simplified as A for the AD biological model) and tau (T) proteins, with Aß emerging first. However, a significant proportion of individuals exhibit discordant biomarkers' profiles, such as elevated phosphorylated tau181 (p-tau181) with normal Aß42 from cerebrospinal fluid (CSF), posing diagnostic and mechanistic challenges. This study investigated whether functional and structural brain connectivity can distinguish individuals with discordant CSF profiles (A-T+) from those with concordant patterns (A+T+), hypothesizing that distinct connectivity patterns may reflect early divergent pathophysiological processes. Data from cognitively unimpaired or mildly impaired individuals in the ADNI3 repository were analyzed, selecting those with resting-state functional MRI (rsfMRI) and/or diffusion MRI (dMRI) within 18 months of CSF testing for Aß and p-tau181. Participants were grouped into A-T+ or A+T+ groups. Structural and functional connectivity gradients were generated for each participant and summarized using a Euclidean distance measure from reference gradient templates derived from cognitively unimpaired individuals without pathology (A-T-). We applied linear mixed models and analysis of variance to assess connectivity-based gradient differences between A-T+ and A+T+ groups, adjusting for relevant variables. Classification analyzes using logistic regression and support vector machine, along with feature importance via the Boruta algorithm, evaluated the discriminative power of gradient connectivity profiles. Multimodal integration was performed using partial least square canonical analysis (PLSC), and relationships between gradients and cognition were assessed via UMAP-based dimensionality reduction and bootstrapped linear regressions. Results were compared with a classical network analysis examining within- and between-network connectivity differences. Among 424 participants, n = 67 were classified as A-T+, n = 106 as A+T+, and n = 56 as cognitively healthy A-T-. The remaining 195 participants (n = 86 A+T+ and n = 109 cognitively impaired A-T-) were not included. A-T+ individuals (age = 75 ± 8.2) exhibited less cognitive impairment but greater functional connectivity gradients' distance to the reference templates (false discovery rate-corrected p < 0.05) in the temporo-occipital axis compared to A+T+ (age = 76.1 ± 7.7). Structural connectivity differences were not significant. FC-based models classified A-T+ and A+T+ with good accuracy (AUC = 0.77), loading on the same temporo-occipital regions, unlike SC (AUC = 0.52). The posterior brain involvement in A-T+ was confirmed by PLSC analyzes. A+T+ individuals showed a significant relation between cognitive scores and functional connectivity, primarily mapping the default mode network (DMN). A shift was observed in relation to executive functions and functional connectivity in A-T+. Discordant CSF profiles (A-T+) exhibit distinct functional connectivity patterns, particularly in posterior brain regions, compared to concordant CSF patterns (A+T+), which are characterized by a significant cognitive-DMN connectivity association. These results suggest that CSF p-tau181 accumulation in the absence of Aß42 may be associated with specific functional trajectories, suggesting specific pathophysiological patterns.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainCognitive DysfunctionConnectomeNerve NetPeptide Fragmentstau ProteinsAgedAged, 80 and overBiomarkersDiffusion Magnetic Resonance ImagingFemaleHumansMagnetic Resonance ImagingMaleAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersMAPT protein, humanPeptide Fragmentstau Proteinsatypical ADbrain connectivitydiffusion MRIresting‐state fMRItau accumulation

Identifiers

PMID41204877
PMCPMC12595544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.